IQVIA (NYSE:IQV) Price Target Cut to $261.00 by Analysts at Stifel Nicolaus

IQVIA (NYSE:IQV) had its price target decreased by Stifel Nicolaus from $273.00 to $261.00 in a research report sent to investors on Friday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the medical research company’s stock.

Several other brokerages have also recently weighed in on IQV. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Morgan Stanley decreased their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Stock Performance

IQV stock opened at $208.13 on Friday. The company has a market cap of $37.78 billion, a P/E ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The stock’s fifty day moving average price is $200.67 and its 200-day moving average price is $219.40.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts forecast that IQVIA will post 10.81 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of IQV. Raymond James Financial Inc. purchased a new stake in shares of IQVIA during the 4th quarter valued at about $236,120,000. FMR LLC lifted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA in the 3rd quarter worth approximately $147,683,000. JPMorgan Chase & Co. increased its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the period. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.